Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Identifier
192024-054
CT.gov Identifier
NCT01298700
EudraCT Identifier
2010-023917-68
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.01% ophthalmic solution
  • bimatoprost 0.03% ophthalmic solution
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Ocular hypertension or glaucoma in each eye * Requires intraocular pressure (IOP)-lowering therapy in both eyes * Best corrected visual acuity of 20/100 or better in each eye
    Exclusion Criteria:
    * Ocular seasonal allergies within 2 years * Required chronic use of ocular medications during the study (intermittent use of artificial tears is allowed) * Ocular surgery or laser within 3 months * Anticipated wearing of contact lenses during the study

    Protocol Summary

    This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.

    Study Locations

    Location
    Status
    Location
    UZ Leuven
    Leuven, Belgium, 3000
    Status
    Not applicable
    Location
    CHU Sart Tilman
    Liège, Belgium, 4000
    Status
    Not applicable
    Location
    University Hospital Brno
    Brno, Czech Republic, 62500
    Status
    Not applicable
    Location
    Eye Clinic
    Frýdštejn, Czech Republic, 463 42
    Status
    Not applicable
    Location
    Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, France, 33076
    Status
    Not applicable
    Location
    Clinique Montcelli
    Marseille, France, 13008
    Status
    Not applicable
    Showing {first} - {last} of {total} Results